口服米索前列醇(PGE1)与阴道地诺前列酮(PGE2)用于引产:随机对照试验个体参与者数据荟萃分析
本个体参与者数据荟萃分析比较口服米索前列醇与阴道地诺前列酮用于引产的效果与安全性。在符合可信度标准的随机对照试验中,两种方法的阴道分娩率及复合围产儿和母亲不良结局均相当。不符合可信度标准的研究报告口服米索前列醇阴道分娩率更高,导致汇总估计值膨胀。
要点
- 符合可信度标准的随机对照试验显示,口服米索前列醇与阴道地诺前列酮的阴道分娩率相当。
- 两种方法的复合围产儿不良结局和复合母亲不良结局均无显著差异。
- 不符合可信度标准的研究报告口服米索前列醇阴道分娩率更高,致汇总估计值膨胀。
核心结论
- 口服米索前列醇或阴道地诺前列酮引产的阴道分娩率及复合围产儿和母亲不良结局相当。
研究设计与样本
- 个体参与者数据荟萃分析,纳入比较口服米索前列醇与阴道地诺前列酮用于单胎活产妊娠引产的随机对照试验。
- 18项符合条件的随机对照试验中,8项提供个体参与者数据,其中5项(1892名参与者)符合TRACT标准。
- 采用两阶段随机效应模型进行个体参与者数据荟萃分析,所有分析均采用意向性治疗原则。
- 对未提供个体参与者数据的随机对照试验,按TRACT评分分层进行聚合数据荟萃分析。
主要发现
- 个体参与者数据荟萃分析显示,口服米索前列醇与阴道地诺前列酮引产后阴道分娩率相似(OR 0.99,95%CI 0.80-1.22;I²=0%)。
- 复合围产儿不良结局率(aOR 1.02,95%CI 0.61-1.72;I²=0%)和复合母亲不良结局率(aOR 1.39,95%CI 0.72-2.69;I²=0%)在两组间也相当。
- 12项符合可信度标准的随机对照试验(5项有个体参与者数据,7项无)的聚合数据荟萃分析也显示,口服米索前列醇与阴道地诺前列酮的阴道分娩率相当(OR 1.08,95%CI 0.92-1.27)。
- 6项不符合可信度标准的研究(3项有个体参与者数据,3项无)报告口服米索前列醇后阴道分娩率更高(OR 1.34,95%CI 1.22-1.48),导致基于所有数据的口服米索前列醇阴道分娩率总体估计值膨胀(OR 1.19,95%CI 1.05-1.36)。
局限性
- 18项符合条件的随机对照试验中仅8项提供个体参与者数据,其中仅5项(1892名参与者)符合TRACT标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness and safety of oral misoprostol vs vaginal dinoprostone for the induction of labor (IOL) using an individual participant data (IPD) meta-analysis. METHODS: We used a Cochrane review and searched Ovid MEDLINE, Ovid Embase, Ovid Emcare, CINAHL Plus, Scopus and ClinicalTrials.gov to identify randomized controlled trials (RCTs) that compared oral misoprostol with vaginal dinoprostone for IOL in viable singleton pregnancies. We invited the authors of eligible trials to share their anonymized data. Primary outcomes were vaginal delivery, a composite measure of adverse maternal outcomes and a composite measure of adverse perinatal outcomes. IPD meta-analysis was conducted using a two-stage random-effects model. An intention-to-treat approach was used for all analyses. Aggregate-data meta-analysis was undertaken with RCTs stratified by Trustworthiness in RAndomised Clinical Trials (TRACT) score. RESULTS: Of 18 eligible RCTs, eight provided IPD, of which five (1892 participants) met the TRACT criteria. IPD meta-analysis showed similar rates of vaginal delivery after IOL with oral misoprostol or vaginal dinoprostone (odds ratio (OR), 0.99 (95% CI, 0.80-1.22); I2 = 0%). The rates of composite adverse perinatal outcome (adjusted odds ratio (aOR), 1.02 (95% CI, 0.61-1.72); I2 = 0%) and composite adverse maternal outcome (aOR, 1.39 (95% CI, 0.72-2.69); I2 = 0%) were also comparable between the groups. Of 10 RCTs that did not share IPD, seven met the TRACT criteria. Aggregate-data meta-analysis of the 12 RCTs (five with IPD and seven without IPD) meeting the trustworthiness criteria also showed comparable rates of vaginal delivery after oral misoprostol and after vaginal dinoprostone (OR, 1.08 (95% CI, 0.92-1.27)). In contrast, six studies not meeting the trustworthiness criteria (three with and three without IPD) reported a higher rate of vaginal delivery following oral misoprostol (OR, 1.34 (95% CI, 1.22-1.48)), resulting in an inflated overall estimate of the vaginal delivery rate after oral misoprostol based on all data (OR, 1.19 (95% CI, 1.05-1.36)). CONCLUSION: IOL with oral misoprostol or vaginal dinoprostone results in comparable rates of vaginal delivery and composite perinatal and maternal adverse outcomes. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Tan SY, Au N, Peel MD, et al. Oral misoprostol (PGE1) vs vaginal dinoprostone (PGE2) for labor induction: individual participant data meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2025. PMID: 41206516. doi:10.1002/uog.70100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。